From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis

How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Schizophrenia research 2005-11, Vol.79 (1), p.59-68
Hauptverfasser: Kapur, Shitij, Mizrahi, Romina, Li, Ming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 68
container_issue 1
container_start_page 59
container_title Schizophrenia research
container_volume 79
creator Kapur, Shitij
Mizrahi, Romina
Li, Ming
description How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.
doi_str_mv 10.1016/j.schres.2005.01.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68651372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092099640500037X</els_id><sourcerecordid>68651372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhq2qiC6FN6hQLuVEwjiJnfWlElpRQKrEBc7WxB53vSRxau8i7Y2H4Al5EtzdlfbGwbJn9P0z1sfYDYeKA5cfNlUy60ipqgFEBbwCaC7YgouuKWsB6pItQNVQKiXbK_YqpQ0AcAHdS3bFZc5wxReM7mMYCxtmHP1ExTYUCQdPkzm857Q365B8-vv7z-Cnn356LHofhvC4f1_Ma4wjmkNV4GRzg6Yw5nPoBHeOv2YvHA6J3pzua_bj_tP31Zfy4dvnr6uPD6VphdyWRilnqG1JWds7WjrTY20c7x1KJS0HJGx7EG3tmppb7CSIpSDqVSNQUtdcs3fHuXMMTztKWz36ZGgYcKKwS1oupeBNV2ewPYImhpQiOT1HP2Lcaw76Wa_e6KNe_axXA9dZb469Pc3f9SPZc-jkMwO3JwCTwcFFnIxPZ67jSkopMnd35Cjb-OUp5m0H69ZHMlttg___T_4BRreexQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68651372</pqid></control><display><type>article</type><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</creator><creatorcontrib>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</creatorcontrib><description>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2005.01.003</identifier><identifier>PMID: 16005191</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult and adolescent clinical studies ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biological and medical sciences ; Chlorpromazine - pharmacology ; Chlorpromazine - therapeutic use ; Dopamine ; Dopamine - metabolism ; Humans ; Medical sciences ; Motivation ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - epidemiology ; Receptors, Dopamine D2 - drug effects ; Salience ; Schizophrenia</subject><ispartof>Schizophrenia research, 2005-11, Vol.79 (1), p.59-68</ispartof><rights>2005 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</citedby><cites>FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S092099640500037X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17196665$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16005191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kapur, Shitij</creatorcontrib><creatorcontrib>Mizrahi, Romina</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</description><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biological and medical sciences</subject><subject>Chlorpromazine - pharmacology</subject><subject>Chlorpromazine - therapeutic use</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Motivation</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - epidemiology</subject><subject>Receptors, Dopamine D2 - drug effects</subject><subject>Salience</subject><subject>Schizophrenia</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAQhq2qiC6FN6hQLuVEwjiJnfWlElpRQKrEBc7WxB53vSRxau8i7Y2H4Al5EtzdlfbGwbJn9P0z1sfYDYeKA5cfNlUy60ipqgFEBbwCaC7YgouuKWsB6pItQNVQKiXbK_YqpQ0AcAHdS3bFZc5wxReM7mMYCxtmHP1ExTYUCQdPkzm857Q365B8-vv7z-Cnn356LHofhvC4f1_Ma4wjmkNV4GRzg6Yw5nPoBHeOv2YvHA6J3pzua_bj_tP31Zfy4dvnr6uPD6VphdyWRilnqG1JWds7WjrTY20c7x1KJS0HJGx7EG3tmppb7CSIpSDqVSNQUtdcs3fHuXMMTztKWz36ZGgYcKKwS1oupeBNV2ewPYImhpQiOT1HP2Lcaw76Wa_e6KNe_axXA9dZb469Pc3f9SPZc-jkMwO3JwCTwcFFnIxPZ67jSkopMnd35Cjb-OUp5m0H69ZHMlttg___T_4BRreexQ</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>Kapur, Shitij</creator><creator>Mizrahi, Romina</creator><creator>Li, Ming</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</title><author>Kapur, Shitij ; Mizrahi, Romina ; Li, Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-c99fce44e9ddbfe8fcba2cf1bfa696d10aea4b0542f321da760585eeb935a6e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biological and medical sciences</topic><topic>Chlorpromazine - pharmacology</topic><topic>Chlorpromazine - therapeutic use</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Motivation</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - epidemiology</topic><topic>Receptors, Dopamine D2 - drug effects</topic><topic>Salience</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapur, Shitij</creatorcontrib><creatorcontrib>Mizrahi, Romina</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapur, Shitij</au><au>Mizrahi, Romina</au><au>Li, Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>79</volume><issue>1</issue><spage>59</spage><epage>68</epage><pages>59-68</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>How does an excess in a neurochemical lead someone to being paranoid about the intentions of their neighbour? And why does blocking a dopamine receptor improve this symptom? In this article we present a heuristic framework which attempts to link the biology, phenomenology and pharmacology of psychosis. Focussing on dopamine's role in reward prediction and motivational salience we propose that psychosis arises from an aberrant assignment of novelty and salience to objects and associations. Antipsychotics block dopamine receptors and decrease dopamine transmission, which leads to the attenuation of aberrant novelty and salience. This ‘salience’ framework accounts for existing data and questions several current assumptions about the speed of onset phenomenological effects of antipsychotics and their behavioral effects in animal models. We review new data to show that in contrast to the prevailing idea of a “delayed onset” of antipsychotic action, the improvement is evident in the first few days. Antipsychotics do not eradicate symptoms, but create a state of “detachment” from them. And the actions of antipsychotics in the conditioned avoidance response model, one of the best established animal models for identifying antipsychotic action, are consistent with the idea that they dampen aberrant as well as normal motivational salience. The article discusses the caveats, limitations as well as the clinical implications of the salience framework.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16005191</pmid><doi>10.1016/j.schres.2005.01.003</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-9964
ispartof Schizophrenia research, 2005-11, Vol.79 (1), p.59-68
issn 0920-9964
1573-2509
language eng
recordid cdi_proquest_miscellaneous_68651372
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult and adolescent clinical studies
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Antipsychotics
Biological and medical sciences
Chlorpromazine - pharmacology
Chlorpromazine - therapeutic use
Dopamine
Dopamine - metabolism
Humans
Medical sciences
Motivation
Neuropharmacology
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Psychosis
Psychotic Disorders - drug therapy
Psychotic Disorders - epidemiology
Receptors, Dopamine D2 - drug effects
Salience
Schizophrenia
title From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A28%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20dopamine%20to%20salience%20to%20psychosis%E2%80%94linking%20biology,%20pharmacology%20and%20phenomenology%20of%20psychosis&rft.jtitle=Schizophrenia%20research&rft.au=Kapur,%20Shitij&rft.date=2005-11-01&rft.volume=79&rft.issue=1&rft.spage=59&rft.epage=68&rft.pages=59-68&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2005.01.003&rft_dat=%3Cproquest_cross%3E68651372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68651372&rft_id=info:pmid/16005191&rft_els_id=S092099640500037X&rfr_iscdi=true